drugset / Trial / NCT00519558

Growth Hormone Deficiency in Adults (GHDA)

NCT00519558

Phase 3 Completed 121 enrolled Novo Nordisk A/S
RandomizedParallel-groupDouble-blindTreatment

Summary

This trial is conducted in Japan. The aim of this trial is to demonstrate superiority of the effect of NN-220 compared with that of placebo as assessed by the change in percent in truncal fat (kg) from baseline to 24 weeks' treatment (end of treatment) in patients with Growth Hormone Deficiency in Adults (GHDA).

Timeline

Start
2003-05-31
Primary completion
2005-01-24
Completion
2005-01-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Somatropin Protein / enzyme biologic 0.012 mg/kg

Indications